Stockreport

Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF subsidiary Priovant Therapeutics had started enrolling patients in a Phase 2b/3 trial of brepocitinib for lichen planopilaris (LPP). LPP is a severe inflammatory hair lo [Read more]